194 related articles for article (PubMed ID: 21045156)
1. Upregulation of DLX5 promotes ovarian cancer cell proliferation by enhancing IRS-2-AKT signaling.
Tan Y; Cheung M; Pei J; Menges CW; Godwin AK; Testa JR
Cancer Res; 2010 Nov; 70(22):9197-206. PubMed ID: 21045156
[TBL] [Abstract][Full Text] [Related]
2. DLX5 (distal-less homeobox 5) promotes tumor cell proliferation by transcriptionally regulating MYC.
Xu J; Testa JR
J Biol Chem; 2009 Jul; 284(31):20593-601. PubMed ID: 19497851
[TBL] [Abstract][Full Text] [Related]
3. A novel recurrent chromosomal inversion implicates the homeobox gene Dlx5 in T-cell lymphomas from Lck-Akt2 transgenic mice.
Tan Y; Timakhov RA; Rao M; Altomare DA; Xu J; Liu Z; Gao Q; Jhanwar SC; Di Cristofano A; Wiest DL; Knepper JE; Testa JR
Cancer Res; 2008 Mar; 68(5):1296-302. PubMed ID: 18316591
[TBL] [Abstract][Full Text] [Related]
4. The homeoprotein Dlx5 drives murine T-cell lymphomagenesis by directly transactivating Notch and upregulating Akt signaling.
Tan Y; Sementino E; Xu J; Pei J; Liu Z; Ito TK; Cai KQ; Peri S; Klein-Szanto AJ; Wiest DL; Testa JR
Oncotarget; 2017 Feb; 8(9):14941-14956. PubMed ID: 28122332
[TBL] [Abstract][Full Text] [Related]
5. MiR-99a suppressed cell proliferation and invasion by directly targeting HOXA1 through regulation of the AKT/mTOR signaling pathway and EMT in ovarian cancer.
Zhang L; Liu XL; Yuan Z; Cui J; Zhang H
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4663-4672. PubMed ID: 31210292
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Ca
Liu Z; Zhang S; Hou F; Zhang C; Gao J; Wang K
Int J Cancer; 2019 May; 144(9):2215-2226. PubMed ID: 30243029
[TBL] [Abstract][Full Text] [Related]
7.
Zhang J; Wu J; Chen Y; Zhang W
Biochem Cell Biol; 2021 Aug; 99(4):424-434. PubMed ID: 34283652
[TBL] [Abstract][Full Text] [Related]
8. Wnt signaling mediates oncogenic synergy between Akt and Dlx5 in T-cell lymphomagenesis by enhancing cholesterol synthesis.
Tan Y; Sementino E; Liu Z; Cai KQ; Testa JR
Sci Rep; 2020 Sep; 10(1):15837. PubMed ID: 32985581
[TBL] [Abstract][Full Text] [Related]
9. Specific inhibition of AKT2 by RNA interference results in reduction of ovarian cancer cell proliferation: increased expression of AKT in advanced ovarian cancer.
Noske A; Kaszubiak A; Weichert W; Sers C; Niesporek S; Koch I; Schaefer B; Sehouli J; Dietel M; Lage H; Denkert C
Cancer Lett; 2007 Feb; 246(1-2):190-200. PubMed ID: 16584837
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-29B (mir-29b) regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3.
Teng Y; Zhang Y; Qu K; Yang X; Fu J; Chen W; Li X
Oncotarget; 2015 Dec; 6(38):40799-814. PubMed ID: 26512921
[TBL] [Abstract][Full Text] [Related]
11. Co-targeting of Akt and Myc inhibits viability of lymphoma cells from Lck-Dlx5 mice.
Tan Y; Sementino E; Pei J; Kadariya Y; Ito TK; Testa JR
Cancer Biol Ther; 2015; 16(4):580-8. PubMed ID: 25793663
[TBL] [Abstract][Full Text] [Related]
12. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
13. Nitric oxide inhibits the proliferation and invasion of pancreatic cancer cells through degradation of insulin receptor substrate-1 protein.
Sugita H; Kaneki M; Furuhashi S; Hirota M; Takamori H; Baba H
Mol Cancer Res; 2010 Aug; 8(8):1152-63. PubMed ID: 20663861
[TBL] [Abstract][Full Text] [Related]
14. HOXB4 knockdown enhances the cytotoxic effect of paclitaxel and cisplatin by downregulating ABC transporters in ovarian cancer cells.
Li Y; Sun J; Gao S; Hu H; Xie P
Gene; 2018 Jul; 663():9-16. PubMed ID: 29660518
[TBL] [Abstract][Full Text] [Related]
15. Increased expression of PITX2 transcription factor contributes to ovarian cancer progression.
Fung FK; Chan DW; Liu VW; Leung TH; Cheung AN; Ngan HY
PLoS One; 2012; 7(5):e37076. PubMed ID: 22615897
[TBL] [Abstract][Full Text] [Related]
16. Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells.
Rosanò L; Spinella F; Di Castro V; Nicotra MR; Dedhar S; de Herreros AG; Natali PG; Bagnato A
Cancer Res; 2005 Dec; 65(24):11649-57. PubMed ID: 16357176
[TBL] [Abstract][Full Text] [Related]
17. c-Met inhibitors attenuate tumor growth of small cell hypercalcemic ovarian carcinoma (SCCOHT) populations.
Otte A; Rauprich F; von der Ohe J; Yang Y; Kommoss F; Feuerhake F; Hillemanns P; Hass R
Oncotarget; 2015 Oct; 6(31):31640-58. PubMed ID: 26436697
[TBL] [Abstract][Full Text] [Related]
18. Mutually exclusive expression of DLX2 and DLX5/6 is associated with the metastatic potential of the human breast cancer cell line MDA-MB-231.
Morini M; Astigiano S; Gitton Y; Emionite L; Mirisola V; Levi G; Barbieri O
BMC Cancer; 2010 Nov; 10():649. PubMed ID: 21108812
[TBL] [Abstract][Full Text] [Related]
19. T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin.
Dziegielewska B; Casarez EV; Yang WZ; Gray LS; Dziegielewski J; Slack-Davis JK
Mol Cancer Ther; 2016 Mar; 15(3):460-70. PubMed ID: 26832797
[TBL] [Abstract][Full Text] [Related]
20. CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells.
Deying W; Feng G; Shumei L; Hui Z; Ming L; Hongqing W
Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28258248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
